central nervous system neoplasms

Summary

Summary: Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.

Top Publications

  1. ncbi Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
    K D Miller
    Division of Hematology and Oncology, Indiana University, Indianapolis, IN 46202, USA
    Ann Oncol 14:1072-7. 2003
  2. ncbi YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
    Andreas F Hottinger
    Brain Tumor Center, New York, NY, USA
    Ann Neurol 70:163-9. 2011
  3. ncbi Bcl-6 predicts improved prognosis in primary central nervous system lymphoma
    Oren Levy
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York, USA
    Cancer 112:151-6. 2008
  4. ncbi Pediatric central nervous system germ cell tumors: a review
    Maria E Echevarría
    Division of Neuro Oncology, Department of Pediatric Hematology Oncology and Stem Cell Transplantation, Children s Memorial Hospital, Chicago, IL, USA
    Oncologist 13:690-9. 2008
  5. pmc The 2007 WHO classification of tumours of the central nervous system
    David N Louis
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Acta Neuropathol 114:97-109. 2007
  6. pmc Age, gender, and racial differences in incidence and survival in primary CNS lymphoma
    J L Villano
    Department of Medicine, Section of Hematology Oncology, University of Illinois at Chicago, Chicago, IL, USA
    Br J Cancer 105:1414-8. 2011
  7. ncbi A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
    Sophie Camilleri-Broet
    Universite Paris Descartes, Faculte de Medecine, Groupe Hospitalier Pitie Salpetriere, AP HP, Paris, France
    Blood 107:190-6. 2006
  8. ncbi Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification
    C H Rickert
    Institute of Neuropathology, University Clinics Münster, Germany
    Childs Nerv Syst 17:503-11. 2001
  9. ncbi Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART)
    Timo Wolf
    Department of Internal Medicine III, Hematology, Oncology and Infectious Diseases, University Hospital Frankfurt, Germany
    Leuk Lymphoma 46:207-15. 2005
  10. pmc Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
    A J Clayton
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Br J Cancer 91:639-43. 2004

Research Grants

  1. Pediatric Cancer, Family Conflict and Child Adjustment
    Lynn Fainsilber Katz; Fiscal Year: 2013
  2. IGF1R: A candidate oncogene in pediatric high grade gliomas
    Claudia P Miller; Fiscal Year: 2012
  3. Oxygen as a master immunologic switch
    Christopher A Pennell; Fiscal Year: 2013
  4. Computational analysis of Human High Grade Gliomas
    Antonio Iavarone; Fiscal Year: 2013
  5. Regulation of oncogenic signal transduction pathways by inositol polyphosphates
    Adam Cain Resnick; Fiscal Year: 2011
  6. 2010 Conference on neurofibromatosis type 2.
    Marco Giovannini; Fiscal Year: 2010
  7. Characterization of GEFT AS a Novel Glioblastoma Oncogene
    MILAN GIRISH CHHEDA; Fiscal Year: 2013
  8. PROTEINASE IN FIBRINOLYSIS AND THROMBOLYTIC THERAPY
    STEVEN GONIAS; Fiscal Year: 1993
  9. AGT DEPLETION FOR THERAPY OF CNS TUMORS
    Jennifer Quinn; Fiscal Year: 2004
  10. Mothers as caregivers for survivors of brain tumors
    Janet Deatrick; Fiscal Year: 2009

Detail Information

Publications278 found, 100 shown here

  1. ncbi Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
    K D Miller
    Division of Hematology and Oncology, Indiana University, Indianapolis, IN 46202, USA
    Ann Oncol 14:1072-7. 2003
    ..As screening central nervous system (CNS) imaging is not routinely performed, the incidence and clinical relevance of occult CNS metastases in advanced breast cancer is unknown...
  2. ncbi YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
    Andreas F Hottinger
    Brain Tumor Center, New York, NY, USA
    Ann Neurol 70:163-9. 2011
    ..To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL)...
  3. ncbi Bcl-6 predicts improved prognosis in primary central nervous system lymphoma
    Oren Levy
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York, USA
    Cancer 112:151-6. 2008
    ..The objectives of this study were to characterize the immunophenotypes of PCNSL samples and to determine their utility in predicting clinical outcomes...
  4. ncbi Pediatric central nervous system germ cell tumors: a review
    Maria E Echevarría
    Division of Neuro Oncology, Department of Pediatric Hematology Oncology and Stem Cell Transplantation, Children s Memorial Hospital, Chicago, IL, USA
    Oncologist 13:690-9. 2008
    ..The standard management for CNS GCTs remains controversial. Treatment regimens aimed to improve progression-free and overall survival times are ongoing...
  5. pmc The 2007 WHO classification of tumours of the central nervous system
    David N Louis
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Acta Neuropathol 114:97-109. 2007
    ....
  6. pmc Age, gender, and racial differences in incidence and survival in primary CNS lymphoma
    J L Villano
    Department of Medicine, Section of Hematology Oncology, University of Illinois at Chicago, Chicago, IL, USA
    Br J Cancer 105:1414-8. 2011
    ..The objective of this study was to analyse the epidemiology, incidence, and outcome of these rare tumours...
  7. ncbi A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
    Sophie Camilleri-Broet
    Universite Paris Descartes, Faculte de Medecine, Groupe Hospitalier Pitie Salpetriere, AP HP, Paris, France
    Blood 107:190-6. 2006
    ..We postulate assigning PCNSL a histogenetic "time-slot," overlapping late GC and early post-GC, that could explain the predominant ABC phenotype observed...
  8. ncbi Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification
    C H Rickert
    Institute of Neuropathology, University Clinics Münster, Germany
    Childs Nerv Syst 17:503-11. 2001
    ..The topography, sex distribution and histology of 340 primary CNS tumors in children up to 17 years of age were investigated and (re-)classified according to the latest WHO classification of nervous system tumors...
  9. ncbi Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART)
    Timo Wolf
    Department of Internal Medicine III, Hematology, Oncology and Infectious Diseases, University Hospital Frankfurt, Germany
    Leuk Lymphoma 46:207-15. 2005
    ....
  10. pmc Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
    A J Clayton
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Br J Cancer 91:639-43. 2004
    ..HER-2-positive breast cancer may have a predilection for the brain, or trastuzumab therapy may change the disease pattern by prolonging survival. New strategies to address this problem require investigation in this group of patients...
  11. ncbi Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy
    Hendrik Pels
    Department of Neurology, University of Bonn, Germany
    J Clin Oncol 21:4489-95. 2003
    ..To evaluate response rate, response duration, overall survival (OS), and toxicity in primary CNS lymphoma (PCNSL) after systemic and intraventricular chemotherapy with deferred radiotherapy...
  12. ncbi High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions
    Andres J M Ferreri
    Unit of Lymphoid Malignancies, Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    Leuk Lymphoma 49:2042-7. 2008
    ..This critical review is focused on the analysis of published experiences on HDC/ASCT in PCNSL in order to provide preliminary answers to the most pressing questions in this field...
  13. ncbi Infectious exposure in the first year of life and risk of central nervous system tumors in children: analysis of day care, social contact, and overcrowding
    N J Harding
    Paediatric Epidemiology Group, Centre for Epidemiology and Biostatistics, University of Leeds, Worsley Building, LS2 9JT, Leeds, UK
    Cancer Causes Control 20:129-36. 2009
    ..However, the effect for social contact outside the home, particularly for PNET/medulloblastomas warrants further investigation...
  14. ncbi Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases
    M Bellinzona
    Department of Neurosurgery, Center for Experimental Neuroocology, Nordstadt Hospital, Haltenhoffstr 41, 30167 Hannover, Germany
    Eur J Surg Oncol 31:100-5. 2005
    ..In this study we present a series of 33 patients with primary CNS lymphomas (PCNSL), many presenting with acute signs of increased intracranial pressure due to large space occupying lesions...
  15. ncbi Great Ormond Street Hospital for Children Registry for congenital melanocytic naevi: prospective study 1988-2007. Part 1-epidemiology, phenotype and outcomes
    V A Kinsler
    Department of Dermatology, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK
    Br J Dermatol 160:143-50. 2009
    ..The aetiology of congenital melanocytic naevi (CMNs) is unknown...
  16. ncbi Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly
    K Fritsch
    Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
    Ann Oncol 22:2080-5. 2011
    ..In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of methotrexate, procarbazine, and lomustine (R-MCP)...
  17. ncbi Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005)
    Dayron Rodriguez
    Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    J Surg Res 156:340-51. 2009
    ..Determine the role of surgery and radiation therapy for patients with malignant CNS ependymomas...
  18. ncbi High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study
    G Illerhaus
    Department of Haematology, University Medical Center Freiburg, Freiburg, Germany
    Ann Oncol 20:319-25. 2009
    ..To reduce neurotoxicity, whole-brain irradiation was reserved for patients not responding to chemotherapy...
  19. pmc Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience
    Lilyana Angelov
    3181 SW Sam Jackson Park Rd, Mailcode L603, Portland, OR 97239, USA
    J Clin Oncol 27:3503-9. 2009
    ....
  20. pmc Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation
    Elisabeth Schorb
    Department of Hematology Oncology, Freiburg University Medical Center, Freiburg, Germany
    Haematologica 98:765-70. 2013
    ..Superiority compared to standard chemotherapy still warrants further investigation...
  21. ncbi How I treat primary CNS lymphoma
    Andres J M Ferreri
    Unit of Lymphoid Malignancies, Department of Onco Hematology, San Raffaele Scientific Institute, Milan, Italy
    Blood 118:510-22. 2011
    ..Herein, these important contributions are analyzed to provide recommendations for everyday practice and the rationale for future trials...
  22. ncbi Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study
    B Kasenda
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    Ann Oncol 23:2670-5. 2012
    ..We report long-term data of patients who were treated according to HCT-ASCT containing protocols...
  23. ncbi Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma
    Jeffrey J Raizer
    Northwestern University, Feinberg School of Medicine, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    Cancer 118:3743-8. 2012
    ..Because methotrexate is an integral part of PCSNL treatment, the authors assessed the antitumor activity and safety of pemetrexed in recurrent PCNSL...
  24. pmc Cognitive functions in primary CNS lymphoma after single or combined modality regimens
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Neuro Oncol 14:101-8. 2012
    ..Cognitive dysfunction was more prevalent in PCNSL survivors treated with WBRT + HD-MTX compared with patients treated with HD-MTX alone...
  25. ncbi HIV disorders of the brain: pathology and pathogenesis
    Luis Del Valle
    Center for Neurovirology and Cancer Biology, Laboratory of Neuropathology and Molecular Pathology, Temple University, Philadelphia, Pennsylvania 19122, USA
    Front Biosci 11:718-32. 2006
    ....
  26. ncbi Prophylactic intrathecal chemotherapy in primary CNS lymphoma
    Monica Sierra del Rio
    Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, 47 83, Boulevard de l Hopital, 75651 Paris, France
    J Neurooncol 106:143-6. 2012
    ..Further studies prospectively investigating the role of intrathecal chemoprophylaxis are warranted for this disease...
  27. ncbi Central nervous system tumours in children: epidemiology and risk factors
    Patricia A McKinney
    Centre of Epidemiology and Biostatistics, Leeds Institute of Genetics Health and Therapeutics LIGHT, University of Leeds, Leeds, United Kingdom
    Bioelectromagnetics . 2005
    ..The rarity of childhood CNS tumours necessitates careful attention being paid to the design of future aetiological studies...
  28. pmc Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
    Mary R Welch
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 14:1304-11. 2012
    ..Aggressive therapy should be offered to select patients irrespective of advanced age...
  29. ncbi Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status
    Keishi Makino
    Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1 1 1 Honjo Kumamoto, Kumamoto 860 8556, Japan
    J Neurooncol 106:155-60. 2012
    ..1 months) and nmMGMT (6.7 months) (P = 0.63). Although some patients were elderly and had been heavily pre-treated, temozolomide resulted in a complete response (CR) in 29% and was well tolerated without any major toxicity...
  30. ncbi Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy
    Tanya M Tekautz
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    J Clin Oncol 23:1491-9. 2005
    ..To describe clinical features, therapeutic approaches, and prognostic factors in pediatric patients with atypical teratoid/rhabdoid tumors (ATRT) treated at St Jude Children's Research Hospital (SJCRH)...
  31. ncbi Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma
    Lakshmi Nayak
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Leuk Lymphoma 54:58-61. 2013
    ..Given the overall modest activity, this regimen should be reserved for patients who are not candidates for other, more aggressive salvage treatments...
  32. ncbi Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
    H J Burstein
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Ann Oncol 16:1772-7. 2005
    ..The aim of this study was to characterize the prevalence and predictors of central nervous system (CNS) metastasis among women with HER2-overexpressing metastatic breast cancer receiving trastuzumab-based therapy...
  33. ncbi Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry
    Joanne M Hilden
    Department of Pediatric Hematology Oncology, The Children s Hospital, The Cleveland Clinic, 9500 Euclid Avenue, Desk S20, Cleveland, OH 44195, USA
    J Clin Oncol 22:2877-84. 2004
    ..The poor outcome with conventional infant brain tumor therapy has resulted in a lack of clear treatment guidelines. A registry has been established to create an outcomes database and to facilitate biology studies for this tumor...
  34. ncbi Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors
    A Marachelian
    Childrens Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles, CA 90027, USA
    Bone Marrow Transplant 41:167-72. 2008
    ..Here, we review results of myeloablative chemotherapy with hematopoietic progenitor cell rescue in brain tumors of different histologies...
  35. ncbi MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
    A J M Ferreri
    Medical Oncology Unit, San Raffaele H Scientific Institute, Universita Vita Salute San Raffaele, Milan, Italy
    Neurology 66:1435-8. 2006
    ..Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained...
  36. ncbi Isolated central nervous system (CNS) relapse in a case of childhood systemic anaplastic large cell lymphoma without initial CNS involvement
    Tetsuya Mori
    Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
    J Pediatr Hematol Oncol 25:975-7. 2003
    ..This case serves to emphasize that isolated CNS relapse without detectable initial CNS involvement can arise even after CNS-prophylactic treatment in pediatric ALCL cases...
  37. ncbi Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01
    Deborah P Waber
    Division of Psychology, Department of Psychiatry, Children s Hospital, Boston, MA 02115, USA
    J Clin Oncol 25:4914-21. 2007
    ....
  38. ncbi Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model
    A Hollender
    Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo, Norway
    Ann Oncol 13:1099-107. 2002
    ..To determine the incidence and risk factors for central nervous system (CNS) relapse in patients with non-Hodgkin's lymphoma (NHL)...
  39. ncbi Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment
    Koen Van Besien
    Department of Medicine, University of Chicago, Chicago, IL 60637 1470, USA
    Leuk Lymphoma 49:52-8. 2008
    ..Although long-term survival has been reported in a minority of patients with isolated CNS recurrence after treatment with methotrexate, more effective regimens are needed if survival times after relapse are to be prolonged...
  40. ncbi BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma
    Kristina M Braaten
    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 9:1063-9. 2003
    ..v. high-dose methotrexate therapy...
  41. pmc Gene expression and angiotropism in primary CNS lymphoma
    James L Rubenstein
    University of California, San Francisco, Division of Hematology Oncology M1282 Box 1270, 94143, USA
    Blood 107:3716-23. 2006
    ..High expression of activated STAT6 in tumors was associated with short survival in an independent set of patients with primary CNS lymphoma who were treated with high-dose intravenous methotrexate therapy...
  42. ncbi Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell
    M Montesinos-Rongen
    Department of Neuropathology, University Hospital of Cologne, Cologne, Germany
    Leukemia 22:400-5. 2008
    ....
  43. ncbi Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
    P O'BRIEN
    Trans Tasman Radiation Oncology Group Department of Radiation Oncology, Newcastle Mater Hospital, Newcastle, New South Wales, Australia
    J Clin Oncol 18:519-26. 2000
    ..To assess, in a multi-institutional setting, the impact on relapse, survival, and toxicity of adding two cycles of intravenous methotrexate to cranial irradiation for immunocompetent patients with primary CNS lymphoma...
  44. ncbi Promoter hypermethylation of the RB1 gene in glioblastomas
    M Nakamura
    International Agency for Research on Cancer, Lyon, France
    Lab Invest 81:77-82. 2001
    ..These results indicate that promoter hypermethylation is a late event during astrocytoma progression and is the major mechanism underlying loss of RB1 expression in glioblastomas...
  45. ncbi High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
    Andres J M Ferreri
    Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy
    Lancet 374:1512-20. 2009
    ..We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma...
  46. ncbi Molecular changes in gliomas
    Marc Sanson
    INSERM U495, Laboratoire de Biologie des Interactions Neurones Glie, Paris, France
    Curr Opin Oncol 16:607-13. 2004
    ....
  47. ncbi Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
    Roelien H Enting
    Department of Neurology, University Hospital, Groningen, The Netherlands
    Neurology 63:901-3. 2004
    ..7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL...
  48. ncbi Prospective trial on topotecan salvage therapy in primary CNS lymphoma
    L Fischer
    Department of Haematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Germany
    Ann Oncol 17:1141-5. 2006
    ..Standard salvage therapy has not been established for recurrent primary central nervous system lymphoma (PCNSL). We report the final results of a prospective study on topotecan chemotherapy in relapsed or refractory PCNSL...
  49. ncbi Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer
    Yosuke Togashi
    Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Thorac Oncol 5:950-5. 2010
    ..We investigated CSF concentrations of erlotinib and its active metabolite OSI-420...
  50. ncbi Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    Raja B Khan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 58:175-8. 2002
    ..Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity...
  51. ncbi Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
    Hendrik Pels
    Department of Neurology, Knappschaftskrankenhaus, University of Bochum, In der Schornau 23 25, Bochum, Germany
    J Neurooncol 91:299-305. 2009
    ..Here, the efficacy and toxicity of this regimen without intraventricular treatment was evaluated in PCNSL...
  52. ncbi Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5711-5. 2006
    ....
  53. ncbi Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma
    Moo Kon Song
    Department of Hematology Oncology, Busan Cancer Center, Pusan National University Hospital Medical Research Institute, Busan, Korea
    J Neurooncol 104:825-31. 2011
    ..Bcl-6 expression was associated with higher PFS and OS in patients having non-deep-site involvement. However, this was counteracted in the group of patients having deep-site involvement of the brain...
  54. ncbi Survival among patients with primary central nervous system lymphoma, 1973-2004
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 44 Binney St, Boston, MA 02115, USA
    J Neurooncol 101:487-93. 2011
    ..55 [95% CI 4.01, 5.16]). Despite treatment advances, survival among PCNSL patients in the United States remains poor. However, in the subset of PCNSL patients who are HIV-negative, survival has improved over time...
  55. ncbi Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Division of Neuro Oncology, University of Washington, Seattle, WA 98109 1023
    Semin Oncol 36:S35-45. 2009
    ..Until techniques capable of detecting NM early are developed, increased awareness of the disease and standardized evaluation are likely to have the greatest impact on improving diagnosis and implementing earlier treatment...
  56. ncbi Classification, incidence and survival analyses of children with CNS tumours diagnosed in Sweden 1984-2005
    Birgitta Lannering
    Department of Pediatrics, The Queen Silvia Children s Hospital, University Hospital, University of Gothenburg, Gothenburg, Sweden
    Acta Paediatr 98:1620-7. 2009
    ..This has raised the question about the type of tumours included in the Swedish Cancer registry. We therefore compared international data to the Swedish Childhood Cancer registry...
  57. ncbi Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
    Antonio M P Omuro
    AP HP Hopital Pitie Salpetriere, Service de Neurologie Mazarin, Universite Paris VI Pierre et Marie Curie, IFR 70, INSERM, Unité U711, Paris, France
    J Neurooncol 85:207-11. 2007
    ..In this study we report outcomes of a consecutive series of PCNSL elderly patients initially treated with an innovative regimen combining methotrexate and temozolomide without radiotherapy or intra-thecal chemotherapy...
  58. ncbi Central nervous system manifestations of marginal zone B-cell lymphoma
    Soley Bayraktar
    Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, FL 33136, USA
    Ann Hematol 89:1003-9. 2010
    ..Primary or secondary CNS involvement by MZBCL display indolent clinical behavior and have a generally favorable prognosis, underlining the importance of their differentiation from aggressive lymphomas that more commonly involve the CNS...
  59. pmc Detection of human cytomegalovirus genome and gene products in central nervous system tumours
    J Sabatier
    Department of Neurosurgery, Purpan Hospital, Place Baylak, 31059 Toulouse Cedex, France
    Br J Cancer 92:747-50. 2005
    ..Our results strongly suggest that HCMV is unlikely to be implicated in the development of human malignant gliomas, at least in French cases...
  60. ncbi Delayed neurotoxicity in primary central nervous system lymphoma
    Antonio M P Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Neurol 62:1595-600. 2005
    ..This delayed neurotoxicity has been poorly defined in the literature, and the underlying mechanisms are unknown...
  61. ncbi Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience
    Douglas E Ney
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 116:4605-12. 2010
    ....
  62. ncbi CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms
    Jens Schittenhelm
    Institute of Brain Research, University of Tuebingen, Tuebingen, Germany
    Histopathology 58:739-49. 2011
    ..The aim of this study was to characterize CD133 expression, and the distribution and morphological features of CD133(+) cells, in primary and secondary human central nervous system (CNS) neoplasms...
  63. ncbi Polyomaviruses and primary central nervous system lymphomas
    Jacinta M Murray
    Department of Pathology, Box 1143, Mount Sinai School of Medicine, New York, NY 11377, USA
    Neurology 63:1299-301. 2004
    ..The authors conclude that polyomaviruses are unlikely to be related to the pathogenesis of most PCNSL...
  64. pmc Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma
    Hendrik Pels
    Department of Neurology, Knappschaftskrankenhaus, University of Bochum, In der Schornau 23 25, D 44892 Bochum, Germany
    Neuro Oncol 12:720-4. 2010
    ..01). Early complete tumor response assessed by MRI after the second of sixth scheduled chemotherapy cycles was highly predictive for both OS and TTF in patients with PCNSL treated in this series...
  65. pmc An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET)
    H A Rogers
    Children s Brain Tumour Research Centre, Queen s Medical Centre, University of Nottingham, D Floor Medical School D32, Nottingham, UK
    Br J Cancer 100:1292-302. 2009
    ..The results suggest that the WNT/beta-catenin pathway plays an important role in the pathogenesis of CNS PNETs. However, activation is not caused by mutations in CTNNB1 or APC in the majority of CNS PNET cases...
  66. ncbi Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma
    Annika Juergens
    Department of Neurology, Knappschaftskrankenhaus, University of Bochum, Bochum, Germany
    Ann Neurol 67:182-9. 2010
    ..To evaluate long-term progression-free survival and overall survival, quality of life, and cognitive function in primary central nervous system lymphoma after systemic and intraventricular chemotherapy without radiotherapy...
  67. ncbi Combined chemotherapy and radiation therapy for CNS germ cell tumors--the Japanese experience
    M Matsutani
    Department of Neurosurgery, Saitama Medical School, Irumagun, Japan
    J Neurooncol 54:311-6. 2001
    ..There were no serious complications attributable to the combination therapy. Our treatment protocols are effective for patients with germinomas and those with an intermediate prognosis...
  68. ncbi Increasing incidence rates of childhood malignant diseases in Sweden during the period 1960-1998
    Ann Charlotte Dreifaldt
    Department of Oncology, University Hospital, SE 701 85 Orebro, Sweden
    Eur J Cancer 40:1351-60. 2004
    ..10% (95% CI=1.41, 2.80), benign brain tumours +3.77% (95% CI=2.47, 5.10), and PNET/medulloblastoma +1.96% (95% CI=0.48, 3.46). Changes in diagnostic criteria and better diagnostic tools may have contributed to these results...
  69. ncbi Further clues concerning the aetiology of childhood central nervous system tumours
    Richard J Q McNally
    Cancer Research UK Paediatric and Familial Cancer Research Group, Central Manchester and Manchester Children s University Hospitals NHS Trust, Hospital Road, Manchester M27 4HA, United Kingdom
    Eur J Cancer 40:2766-72. 2004
    ..An example of such an agent is an infection that occurs in mini-epidemics...
  70. ncbi High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group
    Ph Colombat
    Hematologie, CHU Tours, Cedex, France
    Bone Marrow Transplant 38:417-20. 2006
    ..Sixteen patients are actually in continuous complete response. No evidence of late treatment-related toxicity was observed. This treatment approach appears feasible in newly diagnosed PCNSL with encouraging results...
  71. pmc Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy and childhood malignant central nervous system tumours: the ESCALE study (SFCE)
    Matthieu Plichart
    INSERM, U754, Villejuif, France
    Eur J Cancer Prev 17:376-83. 2008
    ..The study does not suggest an increased risk of CNS tumours related to alcohol consumption during pregnancy...
  72. pmc Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004
    Yuta Shibamoto
    Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Mizuho cho, Nagoya 467 8601, Japan
    Neuro Oncol 10:560-8. 2008
    ..The prognosis improved during the last 10 years. Advantage of radiation plus chemotherapy, especially MTX-containing chemotherapy, over radiation alone was suggested...
  73. pmc School behaviour and health status after central nervous system tumours in childhood
    A W Glaser
    Department of Child Health, University of Nottingham, Queens Medical Centre, UK
    Br J Cancer 76:643-50. 1997
    ..However, the results presented identify these young people as a 'special educational needs' group as defined by the 1981 and 1993 Education Acts...
  74. ncbi Ependymal tumors
    Timothy J Moynihan
    Department of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 4:517-23. 2003
    ..A minority of patients may respond to one of several chemotherapy regimens at the time of recurrence, but the impact of this therapy is limited. Newer treatment strategies are needed...
  75. pmc Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 96:219-30. 2010
    ..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)...
  76. ncbi Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
    Meltem Ekenel
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 113:1025-31. 2008
    ..Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival...
  77. ncbi High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma
    Gerald Illerhaus
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    J Clin Oncol 24:3865-70. 2006
    ....
  78. ncbi Population mixing, childhood leukaemia, CNS tumours and other childhood cancers in Yorkshire
    R C Parslow
    Paediatric Epidemiology Group, Unit of Epidemiology and Health Services Research, University of Leeds, 30 Hyde Terrace, UK
    Eur J Cancer 38:2033-40. 2002
    ....
  79. ncbi Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis
    Lauren E Abrey
    Departments of Neurology and Medicine and the Office of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:4151-6. 2003
    ..To assess the safety and efficacy of intensive methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma (PCNSL)...
  80. ncbi Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy
    Andrés José María Ferreri
    Unit of Lymphoid Malignancies, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    Int J Radiat Oncol Biol Phys 80:169-75. 2011
    ..Nevertheless, no study has focused on the survival impact of radiation parameters, as far as we know, and the optimal radiation schedule remains to be defined...
  81. ncbi Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:5034-43. 2005
    ..We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients...
  82. ncbi Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s
    Yuta Shibamoto
    Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Int J Radiat Oncol Biol Phys 62:809-13. 2005
    ..To investigate whether the prognosis of PCNSL patients treated by radiation alone remains still poor, we investigated the results of radiation monotherapy in the 1990s...
  83. ncbi Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience
    D H Yoon
    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Bone Marrow Transplant 46:105-9. 2011
    ..Median survival time was not reached yet with a 2-year survival rate of 88.9%. The current treatment was feasible with a favorable tolerance profile. However, further regimen optimization is necessary because of high relapse rate...
  84. pmc Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma
    Kang Hyun Sung
    Department of Neurosurgery and Division of Neurooncology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158 Paryong ro, Masanhoewon gu, Changwon, Korea
    J Korean Med Sci 26:551-60. 2011
    ..In particular, it is interesting to note that patients with a PCNSL that is homogeneously enhanced by gadolinium have a higher objective response rate, and a longer progression-free survival and overall survival...
  85. ncbi Prognostic factors in primary central nervous system lymphomas
    Andres J M Ferreri
    Medical Oncology Unit, Department of Oncology, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
    Hematol Oncol Clin North Am 19:629-49, vi. 2005
    ..In the years ahead, a well-established prognostic score will allow the separation of patients into risk groups, which could result in the application of risk-tailored therapeutic strategies...
  86. ncbi Primary CNS lymphoma
    Fred H Hochberg
    Massachusetts General Hospital Boston, MA 02114, USA
    Nat Clin Pract Neurol 3:24-35. 2007
    ..Better tools for earlier diagnosis and monitoring of treatment response will emerge from molecular studies of therapeutic targets...
  87. ncbi Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4570-4. 2006
    ..The purpose of this report is to update the initial results and provide long-term data regarding overall survival, patterns of relapse, and the risk of treatment-related neurotoxicity...
  88. ncbi Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome
    Celalettin Ustun
    Section of Hematology Oncology, Department of Medicine, Medical College of Georgia, 1120 15th Street, BAA 5407, Augusta, GA 30912, USA
    Ann Hematol 88:351-8. 2009
    ..Coexistence of a second primary malignancy may be frequent, and prognosis remains dismal with standard lymphoma therapy. Lastly, the role of HHV-8 in the etiopathogenesis needs further trials...
  89. ncbi Central nervous system lymphoma in children
    L Porto
    Neuroradiology Department, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Pediatr Hematol Oncol 22:235-46. 2005
    ..Knowledge of risk factors in children may help in the early recognition of disease, allowing for timely intervention. This may prompt early biopsy or a conservative management in the appropriate clinical setting...
  90. pmc Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
    Oussama Abla
    Division of Haematology Oncology, Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada
    Clin Cancer Res 17:346-52. 2011
    ..To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL)...
  91. ncbi Meeting report: primary central nervous system lymphoma: standards of care and future perspectives
    Ulrich Herrlinger
    Abteilung für Allgemeine Neurologie, Hertie Institut für Klinische Hirnforschung, Zentrum für Neurologie, Universitat Tubingen, Germany
    Onkologie 28:109-11. 2005
    ....
  92. ncbi Space-time clustering of childhood cancer around the residence at birth
    Richard J Q McNally
    School of Clinical Medical Sciences Child Health and Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom
    Int J Cancer 124:449-55. 2009
    ..For leukemia, NHL and Wilms tumor there is support for exposures occurring at similar times before diagnosis. For leukemia, HL, NHL and CNS tumors, but not Wilms tumor, the findings are consistent with infectious hypotheses...
  93. ncbi Ewing's sarcoma family tumors mimicking primary central nervous system neoplasms
    Brett J Theeler
    United States Army, Department of Medicine Neurology Service, United States
    J Neurol Sci 284:186-9. 2009
    ..Correct diagnosis is essential as the treatment paradigms for both entities differ. We present two cases of isolated central nervous system presentations of ESFTs mimicking primary central nervous system neoplasms.
  94. ncbi Central nervous system-directed therapy in the treatment of childhood acute lymphoblastic leukemia and studies of neurobehavioral outcome: Children's Cancer Group trials
    Thomas A Kaleita
    Department of Psychiatry and Biobehavioral Sciences and The UCLA Neuro Oncology Program, UCLA School of Medicine, 300 Medical Plaza, Los Angeles, CA 90095 6967, USA tkaleit
    Curr Oncol Rep 4:131-41. 2002
    ..Future studies of neurobehavioral outcome are briefly elaborated in the context of current chemotherapy approaches used in the treatment of childhood ALL...
  95. ncbi Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P
    Paul C Nathan
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 47:2488-504. 2006
    ..VHD-MTX achieved similar survival to other CNS-directed therapies without the long-term impact on intelligence, but with substantial acute toxicities...
  96. ncbi International study on low-grade primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Neurol 59:755-62. 2006
    ..The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma...
  97. ncbi Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer
    Young Joo Lee
    Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
    Cancer 116:1336-43. 2010
    ..Patients whose best tumor response was complete response, partial response, or stable disease (> or =90 days) were classified into the group receiving clinical benefit with these drugs...
  98. ncbi Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 111:1085-93. 2008
    ..Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma. Long-term survival is possible in some patients...
  99. ncbi The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms
    Richard A Prayson
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Adv Anat Pathol 12:144-8. 2005
    ..Utilization of cell proliferation markers in the evaluation of tumors can be potentially useful in this endeavor. This review focuses on issues surrounding the utilization of MIB-1 or Ki-67 antibody in the evaluation of CNS neoplasms...
  100. ncbi Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience
    A Silvani
    Department of Neuro Oncology, Istituto Nazionale Neurologico Carlo Besta, Via Celoria, 11, Milan 20133, Italy
    J Neurooncol 82:273-9. 2007
    ..When taking into account the patients with radiotherapy delayed at recurrence, the OS was 48 months and the survival rates were 70% and 60% at 2 years and 5 years, respectively...
  101. ncbi Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Hematol 85:45-50. 2006
    ..In conclusion, long-term survival can be achieved in patients with secondary CNS lymphoma. LDH at CNS manifestation and a CNS response to therapy were significantly associated with survival...

Research Grants63

  1. Pediatric Cancer, Family Conflict and Child Adjustment
    Lynn Fainsilber Katz; Fiscal Year: 2013
    ....
  2. IGF1R: A candidate oncogene in pediatric high grade gliomas
    Claudia P Miller; Fiscal Year: 2012
    ..There is a need for improved understanding of pediatric HGG to identify relevant therapeutic targets for kids. ..
  3. Oxygen as a master immunologic switch
    Christopher A Pennell; Fiscal Year: 2013
    ..Collectively, this knowledge will facilitate groundbreaking approaches to enhance the efficacy of immunotherapy for glioma and other non-central nervous system tumors. ..
  4. Computational analysis of Human High Grade Gliomas
    Antonio Iavarone; Fiscal Year: 2013
    ..We anticipate that the identification of the master genetic programs directing the most aggressive features of malignant gliomas will offer the best possible targets for therapeutic intervention. ..
  5. Regulation of oncogenic signal transduction pathways by inositol polyphosphates
    Adam Cain Resnick; Fiscal Year: 2011
    ..In defining additional regulators of the cancerous state a multitargeted approach towards cancer can be implemented in cancers refractory to monotherapies. ..
  6. 2010 Conference on neurofibromatosis type 2.
    Marco Giovannini; Fiscal Year: 2010
    ..This conference provides a unique forum for scientists, audiologists and clinicians to share their latest research results and to brainstorm about future directions in research. ..
  7. Characterization of GEFT AS a Novel Glioblastoma Oncogene
    MILAN GIRISH CHHEDA; Fiscal Year: 2013
    ..With the most aggressive therapy, median survival is 14.6 months. I propose to characterize a gene, GEFT, that might play a role in formation and maintenance of these tumors...
  8. PROTEINASE IN FIBRINOLYSIS AND THROMBOLYTIC THERAPY
    STEVEN GONIAS; Fiscal Year: 1993
    ..During the next five years, the applicant and the institution share the objective of developing this laboratory into a well established center for hemostasis research in this country...
  9. AGT DEPLETION FOR THERAPY OF CNS TUMORS
    Jennifer Quinn; Fiscal Year: 2004
    ..abstract_text> ..
  10. Mothers as caregivers for survivors of brain tumors
    Janet Deatrick; Fiscal Year: 2009
    ....
  11. PROTEIN KINASE C AND GLIAL TUMOR GROWTH
    Ian Pollack; Fiscal Year: 1999
    ..Taken together, these studies will provide fundamental information on the biology astrocytomas and would form the basis for future clinical application of PKC inhibition in the treatment of astrocytic neoplasms. ..
  12. DIFFERENTIATION AND STROMA-INDUCTION IN NEURAL TUMORS
    LUCIEN RUBINSTEIN; Fiscal Year: 1980
    ....
  13. Regulation- Medulloblastoma Growth by alpha-v integrins
    Tobey Macdonald; Fiscal Year: 2006
    ..The long-range goal of this work is to broaden our understanding of medulloblastoma growth, so that novel biologic therapies may be developed into new treatments for medulloblastoma, the most common malignant brain tumor in children. ..
  14. Mechanisms of Herbal Radiosensitization of Glioma Cells
    Garret Yount; Fiscal Year: 2002
    ..abstract_text> ..
  15. Phase 2 study of [18F] FLT for PET imaging of brain tumors in children [IND 10436
    S Ted Treves; Fiscal Year: 2010
    ..This interdisciplinary project aims to validate and characterized the use of 18F-FLT-PET to evaluate these tumors, which, in turn, is expected to improve disease management and enhance the care of children afflicted with brain tumors. ..
  16. CHILDRENS CANCER GROUP CHAIRMANS AWARD
    Gregory Reaman; Fiscal Year: 2002
    ..S. by 5 percent, to 87 percent, by the year 2003. ..
  17. HUMORAL CYTOTOXIC RESPONSE IN GLIOMA PATIENTS
    William Wood; Fiscal Year: 1980
    ..The methodical examination of the humoral response of patients with central nervous system tumors will lead to refined techniques for the immunodiagnosis and serological monitoring of these patients...
  18. Molecular Classification and Therapy of CNS Lymphomas
    James Rubenstein; Fiscal Year: 2008
    ..We will perform gene expression profile analysis of these tumors from diagnostic specimens obtained from a frozen tumor bank to identify a set of genes, which can be used to predict outcome. ..
  19. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..
  20. PREPHASE I GENE/IMMUNE THERAPY OF MALIGNANT BRAIN TUMOR
    HASSAN FATHALLAH SHAYKH; Fiscal Year: 2001
    ..abstract_text> ..
  21. NABTT-New Approaches to Brain Tumor Therapy (CNSC)
    Tracy Batchelor; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  22. A Phase 2 study of AZD2171 in Recurrent Glioblastoma
    Tracy Batchelor; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  23. CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    Robert M Prins; Fiscal Year: 2010
    ..Thus, this is a mechanistic and translational project that is directly related to our long-term objectives stated above and to the mission of promoting public health. ..
  24. NABTT-Consortium Therapeutic Studies of CNS Malignancies
    Stuart Grossman; Fiscal Year: 2008
    ..abstract_text> ..
  25. NABTC Member Intitution Grant (UCSF Project Leader)
    Susan Chang; Fiscal Year: 2008
    ..The overall goal of this program is to more effectively treat patients with primary brain tumors, especially malignant glioma, with the purpose of increasing the duration and quality of survival. ..
  26. Vaso-occlusive Mechanisms that Induce Hypoxia and Cause Glioma Progression.
    Daniel J Brat; Fiscal Year: 2010
    ..This proposal introduces entirely novel concepts that may explain the highly aggressive properties of GBM and suggests therapeutic approaches that could potentially stabilize its progression. ..
  27. Participating Member Institution in NABTC
    Lisa DeAngelis; Fiscal Year: 2008
    ..abstract_text> ..
  28. Pre-Clinical Trials of GEM Models for Gliomas
    Eric Holland; Fiscal Year: 2007
    ..abstract_text> ..
  29. MN REGIONAL SLEEP DISORDERS CENTER SLEEP ACADEMIC AWARD
    Gerald Rosen; Fiscal Year: 2002
    ....
  30. Modeling the effects of INK4 alpha ARF loss on gliomas
    Eric Holland; Fiscal Year: 2003
    ....
  31. HARVARD PEDIATRIC BRAIN TUMOR CENTER
    Mark Kieran; Fiscal Year: 2003
    ..David Louis). In summary, we will bring the full thrust of a Comprehensive Cancer Center and the full services of a pediatric center to enhance the Consortium and our mutual missions. ..
  32. Intravascular Thrombosis in Glioblastoma
    Daniel Brat; Fiscal Year: 2005
    ..Our emerging model represents a paradigm shift in the understanding of GBM and should lead directly to more effective therapies. ..
  33. Xenogen's IVIS 100 Imaging System
    Mark Kieran; Fiscal Year: 2004
    ..This luciferase-based technology affords a superior method to achieve this aim. ..
  34. CHILDRENS NATIONAL MEDICAL CENTER
    Roger Packer; Fiscal Year: 2003
    ....
  35. Pirfenidone in Children with PNs in NF1
    Roger Packer; Fiscal Year: 2006
    ..Abstract Not Provided ..
  36. Role of Retinal Microvasculature in Posterior Uveitis
    Justine Smith; Fiscal Year: 2006
    ..The studies should also have implications for unrelated diseases affecting the retinal circulation, as well as tissue-specific inflammations and infections at other body sites. [unreadable] [unreadable]..
  37. Comparative DNA Microarray Analysis of Brain Tumors
    Daniel Brat; Fiscal Year: 2006
    ....
  38. NEURODEVELOPMENTAL AND NEURODEGERENTATIVE DISEASE
    Nina Schor; Fiscal Year: 2005
    ..Funding of this program will perpetuate this history at an economically and academically critical time. ..
  39. PROTEIN 4.1 TUMOR SUPPRESSORS IN MENINGIOMA PATHOGENESIS
    David Gutmann; Fiscal Year: 2003
    ..and (3) analyzing the ability of DAL-1 to impair cell growth and motility. These studies are collectively designed to define the role of this novel family of growth regulators in meningioma tumorigenesis and progression. ..
  40. PACAP Modulation of Shh Signaling in Medulloblastoma
    Linda M Liau; Fiscal Year: 2010
    ..The information generated from this research will be of significant direct relevance to public health, as this may potentially lead to the development of a novel therapeutic strategy for patients with medulloblastomas. ..
  41. Bone Marrow Stem Cells: Novel Treatment of Human Glioma
    Frederick F Lang; Fiscal Year: 2010
    ....
  42. Cell Type-Specific Viral Translation in the CNS
    Matthias Gromeier; Fiscal Year: 2006
    ..This principle has shown great promise in pre-clinical studies in experimental animals and in primary explant cultures of human CNS tumors. ..
  43. Growth inhibition of brain tumors by cord blood stem cells
    Jasti S Rao; Fiscal Year: 2010
    ....
  44. CHROMOSOME 19Q GLIOMA TUMOR SUPPRESSOR GENE
    David Louis; Fiscal Year: 2002
    ....
  45. Mentored Patient-Oriented Research Career Development Aw
    David Rizzieri; Fiscal Year: 2004
    ..These results will lead to future improvements in maximizing the anti-tumor effects of allogeneic therapy, hastening immunologic recovery, and minimizing the toxicity of this procedure. ..
  46. QUALITY OF LIFE FOLLOWING SUCCESSFUL THERAPY OF AML
    HENRY NICHOLSON; Fiscal Year: 2001
    ..Completion of this study should help pediatric oncologists fight AML in ways that optimize both survival and QOL. ..
  47. Adjunct rhIL-12 enhance THI response to viral vaccine?
    Mark Jacobson; Fiscal Year: 2004
    ..g. CMV, HSV and HIV). ..
  48. Genetic Consequences of Therapies for Cancer
    John Boice; Fiscal Year: 2009
    ..abstract_text> ..
  49. NEUROFIBROMIN AS A NEGATIVE REGULATOR FOR ASTROCYTES
    David Gutmann; Fiscal Year: 2002
    ....
  50. Suppression of glioma invasion by a bicistronic constuct
    JASTI RAO; Fiscal Year: 2007
    ..RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page .................................................................................................................................................. 1 Description, ..
  51. AIDS-ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM
    David Aboulafia; Fiscal Year: 2005
    ..5. Assist the AMC and the NCI clinical trials cooperative groups and the NIAID ACTUs in the development and implementation of phase III studies if initial efforts of the AMC consortium are successful. ..
  52. Hedgehog, Patched, and Gli in Medulloblastoma
    Howard Weiner; Fiscal Year: 2007
    ..This system provides a unique opportunity to investigate an in vivo animal model of childhood medulloblastoma, and to determine the roles of Ptc and Gli in tumorigenesis. ..
  53. Regulation of p53-mediated apoptosis in gliomas
    Frederick Lang; Fiscal Year: 2007
    ..These studies should help define p53 phosphorylation as a therapeutic target and a marker of p53-mediated apoptosis in gliomas. ..
  54. Identification and Preclinical Evaluation of New Brain Tumor Therapies
    David Gutmann; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  55. Targeted Gene Delivery Against Glioblastoma multiforme
    Michael Lim; Fiscal Year: 2005
    ..2. Establish localization of avb3-NP for endothelial cells of the RT2 tumor. 3. Demonstrate tumor control and improved rat survival in the RT2 model following treatment with avb3-NP affixed to ATP/m-Raf. ..
  56. Assessment of BBB Disruption during RT using DCE MRI
    Yue Cao; Fiscal Year: 2006
    ..Data from these scans will be analyzed to quantify vascular permeability, which related to dose, volume, time, and presence in tumor versus normal brain tissue. ..
  57. First Int'l Symposium on Childhood and Adolescent NHL
    Mitchell Cairo; Fiscal Year: 2003
    ..abstract_text> ..
  58. Image Localization for Pathologic Correlation of Delta-24-RGD
    Charles Conrad; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  59. Control of Cerebellar Development by FGF signaling
    Robert Wechsler Reya; Fiscal Year: 2008
    ..our understanding of cell cycle regulation in normal granule cell precursors, these studies may shed light on the loss of cell cycle control in medulloblastoma, the most common malignant brain tumor in children [unreadable] [unreadable]..
  60. Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
    Mark Jacobson; Fiscal Year: 2008
    ..Thus, understanding the disease mechanism of CMV IRU could facilitate development of effective therapy for CMV IRU or diagnostic or treatment strategies to prevent CMV IRU. [unreadable] [unreadable] [unreadable]..
  61. Social & Physical Activity of Childhood Cancer Survivors
    Debra Friedman; Fiscal Year: 2006
    ..Subjects in the 1C will be compared to an equal number of subjects enrolled in a standard care CC on identical outcome measures. ..
  62. Perceived Cognitive function Item Bank for Children Who Undergo Cancer Treatment
    Jin Shei Lai; Fiscal Year: 2009
    ....